CHICAGO, March 17, 2025--(BUSINESS WIRE)--Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and ...

The projected fair value for Xeris Biopharma Holdings is US$6.17 based on 2 Stage Free Cash Flow to Equity Xeris Biopharma Holdings' US$5.03 share price indicates it is trading at similar levels ...

Xeris Biopharma Holdings, Inc. (Nasdaq: XERS), a growth-oriented biopharmaceutical company committed to improving patient lives by developing and commercializing innovative products across a range ...

Xeris Biopharma (XERS), a fast-growing biopharmaceutical company, beat top and bottom-line expectations for Q4 and announced it is expecting over 30% revenue growth in 2025. The company ...

CHICAGO - Xeris Biopharma Holdings, Inc. (NASDAQ: XERS), a $742 million market cap pharmaceutical company whose stock has surged 116% over the past year, has announced the FDA approval of its ...

Xeris Biopharma (XERS) Holdings announced that its supplemental new drug application, sNDA, of Gvoke VialDx has received U.S Food and Drug Administration FDA approval for use as a diagnostic aid ...

Craig Hallum lifted their target price on shares of Xeris Biopharma from $5.00 to $6.50 and gave the company a “buy” rating in a research report on Friday, March 7th.

Xeris Biopharma (NASDAQ:XERS – Get Free Report)‘s stock had its “buy” rating reissued by investment analysts at HC Wainwright in a research note issued to investors on Friday,Benzinga reports.

Xeris Biopharma has strong revenue growth, with net product revenue reaching $203 million in 2024 and projected to hit $255–275 million in 2025. Key products include Gvoke for severe ...

CHICAGO - Xeris Biopharma Holdings, Inc. (NASDAQ: XERS), a $742 million market cap pharmaceutical company whose stock has surged 116% over the past year, has announced the FDA approval of its ...

CHICAGO (AP) — CHICAGO (AP) — Xeris Biopharma Holdings, Inc. (XERS) on Thursday reported a loss of $5.1 million in its fourth quarter. The Chicago-based company said it had a loss of 3 cents ...